Business Wire

Applications Software Technology Acquires Symatrix to Accelerate Global Expansion in Oracle Cloud Services

20.5.2024 15:00:00 EEST | Business Wire | Press release

Share

Applications Software Technology (AST), a leading digital transformation solutions provider, today announced the signing of a definitive agreement for the acquisition of IT and Oracle services provider Symatrix. The acquisition of Symatrix, a leading IT and Oracle services provider in the UK, is a meaningful step in AST’s global expansion.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240520063933/en/

“The capabilities of Symatrix complement and broaden AST’s core services and allow us to reach new global markets,” said AST CEO Justin Winter. “Working together we will be able to offer enhanced services to our combined customer base. We’ll continue to deliver high-value solutions that provide measurable value and outcomes for our customers at a global scale.”

Symatrix brings an established UK customer base that strengthens AST’s vertical expertise across numerous industries and provides a platform to further expand in emerging sectors. The deep consulting capabilities of Symatrix will also expand AST’s capabilities across Oracle Cloud Applications, including Supply Chain and Human Capital Management.

“AST is a best-in-class enterprise solutions provider that has developed into a premier consultancy for complex Cloud needs across public and commercial industries,” said Chris Brooks, Symatrix CEO. “Joining forces with AST is a natural progression for Symatrix and allows us to service our customers with even greater resources and technical services.”

“AST and Symatrix represent a powerful combination in Oracle Cloud services,” added Charles Phillips -- Managing Partner for Recognize, Chairman of the Board for AST and former President of Oracle. “The complementary end market exposure helps solidify the businesses’ leadership positions across two continents.”

Following the transition, Chris and the leadership team will remain in their roles with a renewed focus on expanding the UK customer base with a new suite of offerings and delivery geographies from AST.

“At AST, we foster a culture of inclusivity and innovation at every level of our organization,” said Winter. “The Symatrix family embodies these values, and our partnership opens a world of exciting possibilities for our customers and employees.”

About Applications Software Technology (AST) LLC

AST is an award-winning, full-service enterprise solution provider, guiding digital transformation for clients in the Government and Commercial Sectors for more than two decades. Clients look to AST for leadership and assistance in transforming their organizations via software solutions, process engineering, and change management. From cloud technology to legacy on-premises applications, AST’s services encompass all aspects of SaaS, PaaS, and IaaS. AST also offers flexible Managed Services, supporting the needs of over 200 customers around the globe. To learn more, visit www.astcorporation.com.

About Symatrix

Symatrix is a United Kingdom based Oracle HCM, ERP and SCM Cloud Consulting, Application Management and Outsourced Payroll provider. Symatrix works with Public Sector and Commercial clients to innovatively help unlock the endless and exciting possibilities of Oracle Cloud.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Melissa Sider
Phone: (888) AST-0002
Email: msider@astcorporation.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye